NewAmsterdam Pharma (NAMS) EBIT Margin (2023 - 2026)
NewAmsterdam Pharma's (NAMS) quarterly EBIT Margin came in at 1921.71% in Q1 2026, up 39276.0% year-on-year from N/an in Q1 2025, and up 99.07% quarter-over-quarter from 206187.5% in Q4 2025.
NewAmsterdam Pharma (NAMS) EBIT Margin (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has disclosed EBIT Margin across 4 years of filings, most recently posting 1921.71% for Q1 2026.
- EBIT Margin for Q1 2026 came in at 1921.71%, up 39276.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 953.59% (down 55111.0% YoY), and the FY2025 annual result was 1002.9%, down 61599.0% from the prior year.
- EBIT Margin came in at 1921.71% for Q1 2026 at NewAmsterdam Pharma, up from 206187.5% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 85.89% in Q3 2024 to a low of 206187.5% in Q4 2025.
- The 4-year median for EBIT Margin is 2306.93% (2024), against an average of 18779.11%.
- Across the five-year window, EBIT Margin jumped 602193 bps in 2024 and slumped 20584903 bps in 2025, its largest moves.
- NewAmsterdam Pharma's EBIT Margin stood at 6360.4% in 2023, then jumped by 95 bps to 338.47% in 2024, then sank by 60818 bps to 206187.5% in 2025, then surged by 99 bps to 1921.71% in 2026.
- The last three EBIT Margin figures came in at 1921.71% (Q1 2026), 206187.5% (Q4 2025), and 15845.69% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | NewAmsterdam Pharma | 3.63 Bn | 3.63 Bn | - | -1,921.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,921.71% |
| Dec 31, 2025 | -206,187.50% |
| Sep 30, 2025 | -15,845.69% |
| Jun 30, 2025 | -186.13% |
| Mar 31, 2025 | -2,314.47% |
| Dec 31, 2024 | -338.47% |
| Sep 30, 2024 | -85.89% |
| Jun 30, 2024 | -2,306.93% |
| Mar 31, 2024 | -3,960.17% |
| Dec 31, 2023 | -6,360.40% |
| Sep 30, 2023 | -1,685.07% |
| Jun 30, 2023 | -2,474.20% |
| Mar 31, 2023 | -461.85% |